Valuation : Actuate Therapeutics, Inc.

Market Cap 39.74M 34.25M 32.11M 29.31M 55.22M 3.8B 55.39M 381M 149M 1.92B 149M 146M 6.36B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 39.74M 34.25M 32.11M 29.31M 55.22M 3.8B 55.39M 381M 149M 1.92B 149M 146M 6.36B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
84.59%
Yield 2026 *
-
Yield 2027 * -
1 day-2.07%
1 week+30.31%
Current month+49.10%
1 month+56.13%
3 months-20.43%
6 months-55.75%
Current year-72.96%
1 week 1.18
Extreme 1.1805
1.97
1 month 0.9
Extreme 0.9
1.97
Current year 0.9
Extreme 0.9
7.05
1 year 0.9
Extreme 0.9
9.22
3 years 0.9
Extreme 0.9
11.99
5 years 0.9
Extreme 0.9
11.99
10 years 0.9
Extreme 0.9
11.99
Manager TitleAgeSince
Chief Executive Officer 64 28/02/2015
Director of Finance/CFO 58 31/01/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 64 31/03/2015
Chairman 46 31/03/2015
Director/Board Member 66 28/02/2021
Date Insider Type Main position Quantity % Market Cap.
14/08/26 Fiscal year

Chief Executive Officer

664,633 2.7779%
21/05/26 Free

Director

15,000 0.0633%
21/05/26 Free

Director

15,000 0.0633%
Change 5-day change 1-year change 3-year change Capi.($)
-2.07%+30.31%-79.87% - 39.74M
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -2.03%+1.30%+45.39%+192.41% 28.2B
Weighted average by Cap. -1.93%-1.50%+57.13%+152.82%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Employees
-
Date Price Change Volume
28/08/26 US$1.655 -2.07% 231,302
27/08/26 US$1.690 -5.06% 366,078
26/08/26 US$1.780 +12.66% 3,304,333
25/08/26 US$1.580 +28.46% 589,187
24/08/26 US$1.230 -3.15% 179,285
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.655USD
Average target price
10.01USD
Spread / Average Target
+504.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACTU Stock